Compare ARK Genomic Revolution ETF (ARKG) vs McDonald's Corp (MCD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs McDonald's Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while McDonald's Corp trades at $276.41 (market cap $195.10B). The key difference: McDonald's Corp pays a 2.71% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, McDonald's Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | MCD | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $341.06 |
52-Week Low | $23.09 | $264.54 |
Market Cap | — | $195.10B |
Volume | — | 2,230,036 |
Enterprise Value | — | $248.82B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
McDonald's (MCD) trades at $274.60, down 0.68% for the day, amid a bearish technical signal and mixed earnings history. The company reported Q1 2026 EPS of $2.83, beating expectations, but missed in Q3 2025. Revenue growth is steady, with 2025 revenue at $26.89B and net income of $8.56B, though long-term debt remains elevated at $38.42B. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and menu improvements to counter competitive pressures.
The outlook is cautiously optimistic, with a consensus price target of $325.50 implying significant upside. Strengths include strong brand loyalty and consistent profitability, but risks include inflation impacting franchisee margins and high debt levels. Analyst sentiment is predominantly bullish, with 59.68% recommending buy, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
